{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:39:25Z","timestamp":1769247565736,"version":"3.49.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejpb.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T20:22:26Z","timestamp":1673036546000},"page":"74-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses"],"prefix":"10.1016","volume":"183","author":[{"given":"Raquel","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Slowing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafaela","family":"Raposo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Paloma Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Jim\u00e9nez-Cebri\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J.","family":"Chamorro-Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bol\u00e1s-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores R.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ejpb.2023.01.003_b0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0213-005X(11)70042-8","article-title":"Antifungal therapy update: new drugs and medical uses","volume":"29","author":"Fort\u00fan","year":"2011","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"10.1016\/j.ejpb.2023.01.003_b0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0140-6736(10)62237-4","article-title":"Combination therapy for visceral leishmaniasis","volume":"377","author":"van Griensven","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejpb.2023.01.003_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2022.101328","article-title":"A systematic review of epidemiology, risk factors, diagnosis, antifungal resistance, and management of invasive aspergillosis in Africa","volume":"33","author":"Yerbanga","year":"2023","journal-title":"J. Med. Mycol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0020","article-title":"La resistencia a los antibi\u00f3ticos y la falta de inter\u00e9s de la industria farmac\u00e9utica","volume":"18","author":"Medina","year":"2014","journal-title":"Infectio"},{"key":"10.1016\/j.ejpb.2023.01.003_b0025","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkr260","article-title":"Effective antibacterials: at what cost? The economics of antibacterial resistance and its control","volume":"66","author":"White","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/dom.12015","article-title":"Combine and conquer: advantages and disadvantages of fixed-dose combination therapy","volume":"15","author":"Bell","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejpb.2023.01.003_b0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.hipert.2016.03.001","article-title":"Medical expert consensus in AH on the clinical use of triple fixed-dose antihypertensive therapy in Spain","volume":"33","author":"Maz\u00f3n","year":"2016","journal-title":"Hipertens Riesgo Vasc"},{"key":"10.1016\/j.ejpb.2023.01.003_b0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11095-020-02847-3","article-title":"Oral fixed-dose combination pharmaceutical products: industrial manufacturing versus personalized 3D printing","volume":"37","author":"Fern\u00e1ndez-Garc\u00eda","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.01.003_b0045","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/ajh\/hpw022","article-title":"Effects of the antihypertensive fixed-dose combinations on an early marker of hypertensive cardiac damage in subjects at low cardiovascular risk","volume":"29","author":"Mazza","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejpb.2023.01.003_b0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1753-0407.12432","article-title":"Efficacy and safety of sitagliptin\/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: a multicenter randomized double-blind study","volume":"9","author":"Kim","year":"2017","journal-title":"J. Diabetes"},{"key":"10.1016\/j.ejpb.2023.01.003_b0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/liv.12964","article-title":"Daclatasvir + asunaprevir + beclabuvir \u00b1 ribavirin for chronic HCV genotype 1-infected treatment-naive patients","volume":"36","author":"Everson","year":"2016","journal-title":"Liver Int."},{"key":"10.1016\/j.ejpb.2023.01.003_b0060","unstructured":"Fungizone 50 mg powder for sterile concentrate, Available from: https:\/\/www.medicines.org.uk\/emc\/product\/10716\/smpc#gref (retrieved on: 1st December 2022)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2022.106661","article-title":"Amphotericin B: a drug of choice for visceral leishmaniasis","volume":"235","author":"Kumari","year":"2022","journal-title":"Acta Trop."},{"key":"10.1016\/j.ejpb.2023.01.003_b0070","unstructured":"AmBisome, data sheet, Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/61117\/FT_61117.html (retrieved on: 1st December 2022)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0075","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1007\/s00436-022-07659-5","article-title":"Liposomal drug delivery systems for the treatment of leishmaniasis","volume":"121","author":"Tuon","year":"2022","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ejpb.2023.01.003_b0080","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1128\/AAC.00052-15","article-title":"In vitro and in vivo efficacy of amphotericin B combined with posaconazole against experimental disseminated sporotrichosis","volume":"59","author":"Mario","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1128\/AAC.48.3.985-991.2004","article-title":"Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis","volume":"48","author":"Larsen","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0090","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1086\/374856","article-title":"Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia","volume":"36","author":"Odds","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2023.01.003_b0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.1983.tb02152.x","article-title":"Absorption of orally administered amphotericin B lozenges","volume":"16","author":"Ching","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/tde.12.134","article-title":"The oral delivery of amphotericin B","volume":"4","author":"Torrado","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2023.01.003_b0105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3109\/10837450.2012.660699","article-title":"Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms","volume":"18","author":"Desai","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2017.04.013","article-title":"Unmet clinical needs in the treatment of systemic fungal infections: the role of amphotericin B and drug targeting","volume":"525","author":"Fern\u00e1ndez-Garc\u00eda","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0115","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jconrel.2021.12.019","article-title":"Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers","volume":"341","author":"Fern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.01.003_b0125","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1021\/acs.molpharmaceut.8b00724","article-title":"Phase diagrams of polymer-dispersed liquid crystal systems of itraconazole\/component immiscibility induced by molecular anisotropy","volume":"15","author":"Kozyra","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0130","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1128\/AAC.00630-06","article-title":"Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation","volume":"50","author":"Mouton","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/ph15040482","article-title":"Augmenting azoles with drug synergy to expand the antifungal toolbox","volume":"15","author":"Kane","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejpb.2023.01.003_b0140","unstructured":"Itraconazole 100 mg capsules, data sheet, Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/65773\/FT_65773.html (retrieved on: 1st December 2022)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0145","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2023.01.003_b0150","unstructured":"C. Anis Yohana, S. Sriwidodo, A. Marline, Microcrystalline cellulose as pharmaceutical excipient, in: A. Usama, A. Juber (Eds.), Pharmaceutical Formulation Design, IntechOpen, Rijeka, 2019, pp. 3."},{"key":"10.1016\/j.ejpb.2023.01.003_b0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2014.02.021","article-title":"Effects of polyvinylpyrrolidone both as a binder and pore-former on the release of sparingly water-soluble topiramate from ethylcellulose coated pellets","volume":"465","author":"Yang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0160","first-page":"815","article-title":"Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations","volume":"25","author":"Rasool","year":"2012","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0165","series-title":"Neonatal Neurology (Fourth Edition)","first-page":"109","article-title":"Chapter 6 - Infectious Diseases","author":"Weitkamp","year":"2007"},{"key":"10.1016\/j.ejpb.2023.01.003_b0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0928-0987(01)00201-9","article-title":"Inulin as filler-binder for tablets prepared by direct compaction","volume":"15","author":"Eissens","year":"2002","journal-title":"Eur. J. Pharm. Sci.: Off. J. Eur. Federat. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0175","article-title":"Potential of Inulin-Fructooligosaccharides Extract Produced from Red Onion (Allium cepa var. viviparum (Metz) Mansf.) as an Alternative Prebiotic Product","volume":"10","author":"Aisara","year":"2021","journal-title":"Plants (Basel)"},{"key":"10.1016\/j.ejpb.2023.01.003_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118817","article-title":"Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale","volume":"573","author":"Fern\u00e1ndez-Garc\u00eda","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1504\/IJPTECH.2011.038107","article-title":"Application of Taguchi and Box-Behnken designs for surface roughness in precision grinding of silicon","volume":"2","author":"Alao","year":"2011","journal-title":"Int. J. Precis. Technol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0190","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1021\/acs.molpharmaceut.6b01034","article-title":"Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections","volume":"14","author":"Rol\u00f3n","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080369","article-title":"Designing fast-dissolving orodispersible films of amphotericin B for oropharyngeal candidiasis","volume":"11","author":"Serrano","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.01.003_b0200","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2014.07.004","article-title":"New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp","volume":"473","author":"Ruiz","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0205","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/bmc.947","article-title":"HPLC assay for determination of amphotericin B in biological samples","volume":"22","author":"Espada","year":"2008","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejpb.2023.01.003_b0210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejpb.2017.11.015","article-title":"Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating","volume":"124","author":"Serrano","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0215","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jphp.12476","article-title":"Cocrystal habit engineering to improve drug dissolution and alter derived powder properties","volume":"68","author":"Serrano","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejps.2016.04.030","article-title":"Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine\/4-aminosalicylic acid cocrystals","volume":"89","author":"Serrano","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0225","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4314\/tjpr.v14i2.5","article-title":"Formulation and in vitro dissolution characteristics of sustained-release matrix tablets of tizanidine hydrochloride","volume":"14","author":"Murtaza","year":"2015","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.01.003_b0230","series-title":"Encyclopedia of Psychopharmacology","first-page":"536","article-title":"First-order elimination kinetics","author":"Wolff","year":"2010"},{"key":"10.1016\/j.ejpb.2023.01.003_b0235","article-title":"Release kinetics \u2013 concepts and applications","author":"Paarakh","year":"2019","journal-title":"Int. J. Pharm. Res. Technol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0240","series-title":"Stability of Drugs and Dosage Forms","isbn-type":"print","author":"Yoshioka","year":"2002","ISBN":"https:\/\/id.crossref.org\/isbn\/9780306468292"},{"key":"10.1016\/j.ejpb.2023.01.003_b0245","unstructured":"C.o. Europe, Biological tests, in: European Pharmacopoeia 10.0, 2019, pp. 207."},{"key":"10.1016\/j.ejpb.2023.01.003_b0250","first-page":"e50166","article-title":"Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs","author":"Evans","year":"2013","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejpb.2023.01.003_b0255","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejps.2016.12.030","article-title":"Analgesic and anti-inflammatory controlled-released injectable microemulsion: pseudo-ternary phase diagrams, in vitro, ex vivo and in vivo evaluation","volume":"101","author":"Pineros","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0260","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ejpb.2023.01.003_b0265","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1021\/acs.cgd.8b00933","article-title":"Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications","volume":"18","author":"Karimi-Jafari","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2023.01.003_b0270","unstructured":"N. Park, K. Shin, M. Kang, F. Dowd, B. Johnson, A. Mariotti, Pharmacology and Therapeutics for Dentistry, 2017."},{"key":"10.1016\/j.ejpb.2023.01.003_b0275","unstructured":"Introduction to tableting by wet granulation, Available from: https:\/\/www.dfepharma.com\/-\/media\/documents\/technical-documents\/technical-papers\/introduction-to-tableting-by-wet-granulation.pdf (retrieved on: 1st December 2019)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000191209","article-title":"Effect of oral glutamine on enterocyte turnover during methotrexate-induced mucositis in rats","volume":"79","author":"Sukhotnik","year":"2009","journal-title":"Digestion"},{"key":"10.1016\/j.ejpb.2023.01.003_b0285","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3390\/nu5041417","article-title":"Fiber and prebiotics: mechanisms and health benefits","volume":"5","author":"Slavin","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.ejpb.2023.01.003_b0290","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1002\/jps.24544","article-title":"The disintegration process in microcrystalline cellulose based tablets, Part 1: influence of temperature, porosity and superdisintegrants","volume":"104","author":"Yassin","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0295","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/mp500527x","article-title":"Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles","volume":"12","author":"Serrano","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcrysgrow.2016.07.001","article-title":"Spring and parachute: How cocrystals enhance solubility","volume":"62","author":"Bavishi","year":"2016","journal-title":"Prog. Cryst. Growth Charact. Mater."},{"key":"10.1016\/j.ejpb.2023.01.003_b0305","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/jps.20906","article-title":"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations","volume":"96","author":"Guzm\u00e1n","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0310","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/aic.690330621","article-title":"On apparent second-order kinetics","volume":"33","author":"Ho","year":"1987","journal-title":"AIChE J"},{"key":"10.1016\/j.ejpb.2023.01.003_b0315","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.71.011908","article-title":"Nucleation and growth in one dimension. I. The generalized Kolmogorov-Johnson-Mehl-Avrami model","volume":"71","author":"Jun","year":"2005","journal-title":"Phys. Rev. E Stat. Nonlin. Soft Matter Phys."},{"key":"10.1016\/j.ejpb.2023.01.003_b0320","doi-asserted-by":"crossref","DOI":"10.1002\/app.40280","article-title":"Modeling of the degradation kinetics of biodegradable scaffolds: the effects of the environmental conditions","volume":"131","author":"Heljak","year":"2014","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.ejpb.2023.01.003_b0325","unstructured":"Amphotericin B, drug bank information, Available from: https:\/\/www.drugbank.ca\/drugs\/DB00681 (retrieved on: 23rd December 2019)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0330","doi-asserted-by":"crossref","unstructured":"M.A. Pfaller, D.J. Diekema, D.L. Gibbs, V.A. Newell, E. Nagy, S. Dobiasova, M. Rinaldi, R. Barton, A. Veselov, Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005, J. Clin. Microbiol. 46 (2008) 515\u2013521.","DOI":"10.1128\/JCM.01915-07"},{"key":"10.1016\/j.ejpb.2023.01.003_b0335","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2013.02.038","article-title":"Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations","volume":"447","author":"Serrano","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0340","unstructured":"Amphotericin B, data sheet, available from: https:\/\/www.sigmaaldrich.com\/deepweb\/assets\/sigmaaldrich\/product\/documents\/134\/925\/a9528dat.pdf (retrieved on the 15th December 2019)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0345","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0350","unstructured":"Itraconazole, data sheet, Available from: https:\/\/www.drugbank.ca\/drugs\/DB01167 (retrieved on: 20th January 2020)."},{"key":"10.1016\/j.ejpb.2023.01.003_b0355","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jac\/43.2.305","article-title":"Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus","volume":"43","author":"Arredondo","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0360","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijpharm.2016.12.047","article-title":"Optimization and evaluation of Oridonin-loaded Soluplus\u00ae-Pluronic P105 mixed micelles for oral administration","volume":"518","author":"Ke","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.01.003_b0365","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2885.2005.00656.x","article-title":"Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos)","volume":"28","author":"Tell","year":"2005","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2023.01.003_b0370","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/IDR.S152473","article-title":"Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies","volume":"11","author":"Fiore","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ejpb.2023.01.003_b0375","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/jac\/dkq358","article-title":"Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009)","volume":"65","author":"Gershkovich","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejpb.2023.01.003_b0380","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1476-511X-10-135","article-title":"Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model","volume":"10","author":"Sivak","year":"2011","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejpb.2023.01.003_b0385","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/jcp.2002.002923","article-title":"Biochemical markers of acute pancreatitis","volume":"59","author":"Matull","year":"2006","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejpb.2023.01.003_b0390","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/ndt\/gfs038","article-title":"Significance of hypo- and hypernatremia in chronic kidney disease","volume":"27","author":"Kovesdy","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejpb.2023.01.003_b0395","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1211\/jpp.60.1.0008","article-title":"Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments","volume":"60","author":"McConnell","year":"2010","journal-title":"J. Pharm. Pharmacol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:50:24Z","timestamp":1760547024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":79,"alternative-id":["S0939641123000036"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}